$111.890
-2.014 (-1.80%)At close
MNPR Comparative Benchmarking
In the context of the broader market, MNPR competes directly with industry leaders such as AURA and NGNE. With a market capitalization of $758.74M, it holds a significant position in the sector. When comparing efficiency, MNPR's gross margin of N/A stands against AURA's N/A and NGNE's N/A. Such benchmarking helps identify whether Monopar Therapeutics Inc. is trading at a premium or discount relative to its financial performance.
Monopar Therapeutics Inc Financial Performance
The company has faced significant net losses, with Q2 2026 net income at -5,313,300 USD, but it has shown a positive EPS of 0.62 in Q2 2026, indicating potential recovery.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.